Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3SH
|
|||
| Former ID |
DCL001119
|
|||
| Drug Name |
Pyroxamide
|
|||
| Synonyms |
POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [1] | |
| Company |
National Cancer Institute (NCI)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H19N3O3
|
|||
| Canonical SMILES |
C1=CC(=CN=C1)NC(=O)CCCCCCC(=O)NO
|
|||
| InChI |
1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)
|
|||
| InChIKey |
PTJGLFIIZFVFJV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 382180-17-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
524991, 4608854, 8153077, 11438689, 12015417, 14848177, 29224069, 50603092, 57322560, 87226485, 99375471, 103418141, 103841418, 104004372, 104253510, 104307980, 117537758, 124757633, 125164437, 126660957, 126731468, 135088920, 136340341, 136367808, 139449345, 143499434, 152039182, 152234894, 152344512, 162011454, 162037804, 162205056, 162403572, 163180667, 163908018, 164042817, 174006330, 177748468, 198971555, 223385536, 223496134, 223669160, 223704764, 226519078, 242059956, 247285530, 249582969, 252158030, 252160464, 252220198
|
|||
| ChEBI ID |
CHEBI:93953
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018698) | |||
| REF 2 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | |||
| REF 3 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.